Google continued to reveal pieces of its expansion into life sciences this week, with a typically ambitious plan to map the characteristics of a healthy human the latest project to go public. The initiative is underpinned by Google's standard building blocks: data and computing horsepower.
Researchers have developed a computational cancer model to predict how a drug will perform in humans, VentureBeat reports.
With the European Parliament's summer break causing progress on new General Data Protection Regulations to stop, cancer experts have taken the opportunity to criticize the proposal. Opponents of the changes warn they could make it practically impossible for researchers to access patient data for cancer research.
With IT playing a bigger and bigger role across the R&D process, market research shop Grand View Research has tipped the computational biology market to achieve a compound annual growth rate (CAGR) of 21.1% over the next six years. And that trajectory will result in the value of the sector topping $4.2 billion by 2020.
The psychiatric sector received a big boost this week when the Broad Institute was given $650 million to investigate the genetic causes of mental illnesses such as schizophrenia and bipolar disorder. And the impact of the work is set to extend far beyond Cambridge, with Broad making the data available to researchers around the world.
The rise of electronic health records was heralded as a step toward the merging of patient care and research, a scenario in which data from the day-to-day of healthcare is gathered to inform treatment and drug development. But a study in the United Kingdom suggests that while technology can now facilitate this vision, the path is blocked by another barrier: red tape.
The deal gives Google a partner with healthcare experience to commercialize the glucose-recording contact lens technology it unveiled earlier this year.
While virtual biotechs and the service providers that support them have been around for years, Transcriptic and rival West Coast startups think they can improve the model through automation. And having raised cash from Google's venture unit and struck deals with some elite academic centers, Transcriptic is now rolling out the next phase of its plan.
The FDA is continuing to push ahead with its openFDA initiative, with this week's rollout of an application programming interface (API) for recall data coming a month after its adverse event system went live. And the regulator plans to maintain the pace throughout the rest of the summer.
Codexis strengthened its ties to small-molecule synthesis this week through a deal with GlaxoSmithKline. The agreement will see GSK pay $6 million upfront and more in milestones to license the platform.
Over the first few months of 2014, Novartis quietly began laying off workers, shedding an estimated 3,000 jobs in four months. Now BioSpace has provided details of where the ax has fallen and why, with development IT teams suffering heavy job losses.
This week a German team presented data from a database analysis study that found a link between a diabetes drug and a slight dip in the risk of developing Alzheimer's.
When Illumina unveiled its HiSeq X Ten in January, the alignment between its capabilities and the needs of England's 100K Genome Project were clear. The project aims to sequence 100,000 genomes by 2017 for around $160 million, figures that only look achievable using the massive output and relatively low costs of the HiSeq X Ten. This week the tie-up became official.
After weeks of increasingly confident media speculation, Google has confirmed it is setting up an outpost of its venture capital wing in Europe. And with a brief to follow a similar strategy to the U.S. team that invested in Flatiron Health, DNAnexus and other biotech IT startups, the $100 million fund is a new source of capital for European life science innovators.
The drug is approved for treating--not preventing--hepatitis B, prompting FDA to call the advert misleading.
Although Numenta has made progress in creating apps that reproduce the brain, it thinks a fully functioning model is impossible without rethinking the underlying hardware.
PHT unveiled its electronic patient reported outcome app for Apple and Android devices last summer, but Google's platform has become its primary focus.
Two hundred eighty scientists have signed an open letter threatening to boycott Europe's Human Brain Project. The scientists have fundamental concerns about exactly what Europe is trying to achieve with its €1 billion ($1.4 billion) budget.
Over the past few years, Google has expanded into life sciences, with venture capital investments, the creation of Calico and development of "smart" contact lenses giving it multiple beachheads in the industry. But the search giant's co-founders have reservations about getting deep into healthcare, saying regulations make it a "painful" sector in which to work.
When the FDA laid out its strategic priorities for 2011 to 2015, the agency listed the modernization of its IT infrastructure as a primary objective. Since then, the FDA has seen another chief information officer pass through its revolving doors and faced criticism from the Government Accountability Office, but is still plugging away with the IT modernization agenda in its next strategic plan.